Zentiva has signed a definitive agreement to acquire Alvogen’s business in central and eastern Europe for an undisclosed fee. The transaction, which is scheduled to close in the first quarter of 2020, subject to customary approvals, marks the latest move to consolidate in the European off-patent market since Zentiva was acquired last year from Sanofi by private-equity investor Advent International.
Alvogen’s CEE operation markets over 200 generic and over-the-counter products across multiple therapeutic areas, consisting of brands like Lactacyd intimate...
